76 related articles for article (PubMed ID: 24956628)
1. [Chronic myeloid Leukemia - clinical practice according to the JSH guideline for hematological malignancies].
Yahagi Y
Gan To Kagaku Ryoho; 2014 May; 41(5):567-71. PubMed ID: 24956628
[No Abstract] [Full Text] [Related]
2. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
3. [Standard therapy for chronic myelogenous leukemia].
Kimura S
Rinsho Ketsueki; 2012 Oct; 53(10):1571-80. PubMed ID: 23037729
[No Abstract] [Full Text] [Related]
4. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Xu LP; Huang XJ
Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
[No Abstract] [Full Text] [Related]
6. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
7. Dasatinib (Sprycel) for CML and Ph + ALL.
Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
[No Abstract] [Full Text] [Related]
8. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
9. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
Rosti G; Baccarani M
Lancet Oncol; 2005 Sep; 6(9):722-3. PubMed ID: 16161267
[No Abstract] [Full Text] [Related]
10. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y
Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukaemia.
Apperley JF
Lancet; 2015 Apr; 385(9976):1447-59. PubMed ID: 25484026
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
14. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
15. [Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia].
Usui N
Gan To Kagaku Ryoho; 2011 May; 38(5):744. PubMed ID: 21717663
[No Abstract] [Full Text] [Related]
16. Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
Racil Z; Klamova H; Voglova J; Faber E; Razga F; Zackova D; Buresova L; Cetkovsky P; Mayer J
Am J Hematol; 2010 May; 85(5):386-9. PubMed ID: 20425803
[No Abstract] [Full Text] [Related]
17. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
18. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
19. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
20. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]